

Timor-Leste

Population 2018

1.3 million

Estimates of TB burden ^o , 2018	Number (thousands)	Rate (per 100 000 population)
Total TB incidence	6.3 (4.1–9)	498 (322–711)
HIV-positive TB incidence	0.077 (0.044–0.12)	6.1 (3.5–9.5)
MDR/RR-TB incidence ^{oo}	0.24 (0.082–0.48)	19 (6.4–38)
HIV-negative TB mortality	1.2 (0.71–1.8)	94 (56–142)
HIV-positive TB mortality	<0.01 (0–0.025)	0.39 (0–2)

Estimated proportion of TB cases with MDR/RR-TB, 2018

New cases	3.1% (1.1–6.1)
Previously treated cases	15% (7.8–23)

TB case notifications, 2018

Total new and relapse	3 782
- % tested with rapid diagnostics at time of diagnosis	1%
- % with known HIV status	77%
- % pulmonary	83%
- % bacteriologically confirmed ^{ooo}	55%
- % children aged 0–14 years	8%
- % women	39%
- % men	53%
Total cases notified	3 906

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2018	60% (42–93)
TB patients facing catastrophic total costs, 2017	83% (80–86)
TB case fatality ratio (estimated mortality/estimated incidence), 2018	20% (10–32)

TB/HIV care in new and relapse TB patients, 2018

	Number	(%)
Patients with known HIV status who are HIV-positive	37	1%
- on antiretroviral therapy	37	100%

Drug-resistant TB care, 2018

% of bacteriologically confirmed TB cases tested for rifampicin resistance ^{ooo}	
- New cases	
- Previously treated cases	
Laboratory-confirmed cases*	MDR/RR-TB: 12, XDR-TB: 0
Patients started on treatment**	MDR/RR-TB: 12, XDR-TB: 0
MDR/RR-TB cases tested for resistance to second-line drugs	0

Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2017	88%	3 470
Previously treated cases, excluding relapse, registered in 2017	92%	109
HIV-positive TB cases registered in 2017	28%	25
MDR/RR-TB cases started on second-line treatment in 2016	83%	6
XDR-TB cases started on second-line treatment in 2016	0	0

TB preventive treatment, 2018

% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	99% (91–100)

TB financing, 2019

National TB budget (US\$ millions)	3.2
Funding source: 15% domestic, 85% international, 0% unfunded	

^o Ranges represent uncertainty intervals

^{oo} MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin


^{ooo} Calculated for pulmonary cases only

* Includes cases with unknown previous TB treatment history

** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed


Tuberculosis profile

(Rate per 100 000 population per year)




Legend:
■ Total TB incidence
■ New and relapse TB cases notified
■ HIV-positive TB incidence

(Rate per 100 000 population per year)




Legend:
■ HIV-negative TB mortality

Notified cases by age group and sex, 2018




Legend:
■ Females ■ Males Incidence

Treatment success rate (%)



Legend:
■ New and relapse
■ Retreatment, excluding relapse
■ HIV-positive ■ MDR/RR-TB ■ XDR-TB

Total budget (US\$ millions)



Legend:
■ Unfunded
■ Funded internationally
■ Funded domestically